Cargando…
Antiplatelet Activity of a Newly Synthesized Novel Ruthenium (II): A Potential Role for Akt/JNK Signaling
In oncotherapy, ruthenium complexes are considered as potential alternatives for platinum compounds, and have been proved as promising anticancer drugs with high efficacy and lesser side effects. Platelet activation plays a major role in cancer metastasis and progression. Hence, this study explored...
Autores principales: | Khamrang, Themmila, Hung, Kuo-Chen, Hsia, Chih-Hsuan, Hsieh, Cheng-Ying, Velusamy, Marappan, Jayakumar, Thanasekaran, Sheu, Joen-Rong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454829/ https://www.ncbi.nlm.nih.gov/pubmed/28448438 http://dx.doi.org/10.3390/ijms18050916 |
Ejemplares similares
-
Possible Molecular Targets of Novel Ruthenium Complexes in Antiplatelet Therapy
por: Jayakumar, Thanasekaran, et al.
Publicado: (2018) -
Structure-Antiplatelet Activity Relationships of Novel Ruthenium (II) Complexes: Investigation of Its Molecular Targets
por: Hsia, Chih-Hsuan, et al.
Publicado: (2018) -
A novel ruthenium (II)-derived organometallic compound, TQ-6, potently inhibits platelet aggregation: Ex vivo and in vivo studies
por: Hsia, Chih-Hsuan, et al.
Publicado: (2017) -
Author Correction: A novel ruthenium (II)-derived organometallic compound, TQ-6, potently inhibits platelet aggregation: Ex vivo and in vivo studies
por: Hsia, Chih-Hsuan, et al.
Publicado: (2020) -
Structure–Activity Relationship Study of Newly Synthesized Iridium-III Complexes as Potential Series for Treating Thrombotic Diseases
por: Yang, Chih-Hao, et al.
Publicado: (2018)